← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 1993First marketed drug
Jan 1, 1973First NDA
Dec 9, 1983Last known activity
Aug 1, 2026
Acquired by Sanofi-Synthelabo → Sanofi-Aventis on Jan 1, 1999
Timeline
1970s
- Jan 1, 1973
Sanofi— Founded
1980s
- Jan 1, 1980
Clin Midy— Acquired
- Dec 9, 1983
aluminum hydroxide— NDA Secondary Org
- Dec 9, 1983
magnesium trisilicate— NDA Organization
1990s
- Jan 1, 1993
Chinoin— Acquired
- Jan 1, 1994
Kodak— Acquired
- Jan 1, 1999
Sanofi-Synthelabo— Acquired By
2000s
- Jan 1, 2004
Sanofi-Aventis— Now
2020s
- Jul 16, 2021
fexinidazole— Marketing Organization
Drugs by trial phase (618 distinct, 2352 trials)
Phase 4 (178 own, 0 via acquisition)
Phase 3 (199 own, 0 via acquisition)
Phase 2 (170 own, 0 via acquisition)
Phase 1 (66 own, 0 via acquisition)
Other trials (5 own, 0 via acquisition)
Indications
Approved for
Studied for
- Abdominal Neoplasms
- Abdominal Pain
- Acidosis
- Acne Vulgaris
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Adenocarcinoma of Lung
- Adenoma, Islet Cell
- Albuminuria
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
- Anemia, Sickle Cell
- Angina Pectoris
- Angina, Stable
- Angina, Unstable
- Angioedema
- Anxiety Disorders
- Aortic Valve Stenosis
- Apnea
- Arrhythmias, Cardiac
- Arterial Occlusive Diseases
- Arteriosclerosis
- Arteritis
- Arthritis
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Ascites
- Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
- Asthma
- Asthma, Exercise-Induced
- Astrocytoma
- Atherosclerosis
- Atrial Fibrillation
- Atrial Flutter
- Atrial Remodeling
- Attention Deficit Disorder with Hyperactivity
- Back Pain
- Bacterial Infections
- Basal Cell Carcinoma
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Bipolar Disorder
- Blindness
- Blood Platelet Disorders
- Body Weight
- Bone Diseases, Metabolic
- Brain Infarction
- Brain Neoplasms
- Breast Neoplasms
- Bronchitis
- Bronchitis, Chronic
- Brugada Syndrome
- Burns
- Calcinosis
- Calculi
- Cancer Pain
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Medullary
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiovascular Diseases
- Carotid Stenosis
- Cerebral Infarction
- Cheyne-Stokes Respiration
- Chickenpox
- Cholangiocarcinoma
- Cholera
- Chronic Pain
- Clostridium Infections
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colles' Fracture
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Congenital Abnormalities
- Constipation
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Cough
- Cystadenocarcinoma
Marketed drugs (20)
Subsidiaries (3 direct, 14 total across the full acquisition tree)
Recent trials (50)
- NCT04877132Study directorN/A—
- NCT04877132Lead sponsorN/A—
- NCT05906706CollaboratorN/A—
- NCT03492489CollaboratorN/A—
- NCT06832865CollaboratorPhase 2Aug 1, 2026
- NCT07133425CollaboratorPhase 2Feb 5, 2026
- NCT07309614CollaboratorPhase 3Jan 31, 2026
- NCT07184944Lead sponsorPhase 3Jan 29, 2026
- NCT07286214Lead sponsorPhase 4Jan 19, 2026
- NCT07112378CollaboratorPhase 3Jan 13, 2026
- NCT07185009Lead sponsorPhase 3Jan 7, 2026
- NCT07225569Lead sponsorPhase 2Dec 26, 2025
- NCT07222189Lead sponsorPhase 2Dec 24, 2025
- NCT07285460Lead sponsorPhase 3Dec 19, 2025
- NCT07272629Lead sponsorPhase 1Dec 3, 2025
Details
- Founded
- Paris, FR Jan 1, 1973
- First NDA
- Dec 9, 1983
- Last known activity
- Aug 1, 2026
Designations held
- Priority review